Comtan

(entacapone)

Phase 2Small molecule

Orion Corporation, Orion Pharma

Comtan is one of 105 small molecule programs targeting Orthostatic Intolerance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

104

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Orthostatic IntoleranceActive, not recruiting

Weight LossActive, not recruiting

Parkinson's DiseaseCompleted

SchizophreniaActive, not recruiting

Orthostatic IntolerancePhase 1/Phase 2

Active, not recruiting

Weight LossPhase 1/Phase 2

Active, not recruiting

Parkinson's DiseasePhase 2

Completed

SchizophreniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Comtan

Orion Corporation, Orion Pharma

Phase 2

1 2

Celexa

AbbVie

Preclinical

4 3

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 4

Ozempic

Novo Nordisk

Preclinical

1 5

Resotran

Takeda

Preclinical

1 6

Catapres

Boehringer Ingelheim

Preclinical

1 7

Inversine

TTargacept Inc.

Preclinical

1 8

Permax

VValeant Pharmaceuticals

Preclinical

1 9

Orap

Teva

Preclinical

2 10

Pitressin

AAultman Health Foundation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Active, not recruiting

Orthostatic Intolerance

NCT00262470

Clinical

Trials by Indication[1]

Parkinson's Disease3 trials

An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

Completed· Novartis logo

Novartis·Phase 2·NCT00237263·285 enrolled

A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

Completed·NNeuroDerm Ltd.·Phase 1·NCT02096601·16 enrolled

A Phase IIa Multicenter, Randomized, Double-blind, Placebo-controlled Study Followed by an Open-label Period, to Evaluate the Safety, Tolerability, and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Subcutaneous ND0612

Completed·NNeuroDerm Ltd.·Phase 2·NCT01883505·30 enrolled

Levodopa2 trials

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Completed·BBial - Portela C S.A.·Phase 1·NCT01519284·82 enrolled

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Completed·BBial - Portela C S.A.·Phase 1·NCT02170376·80 enrolled

Tics2 trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers

Completed· Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma·Phase 1·NCT01840423·101 enrolled

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers

Completed· Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma·Phase 1·NCT01688089·67 enrolled

Orthostatic Intolerance1 trial

Treatment of Orthostatic Intolerance

Active, not recruiting·SSatish R. Raj·Phase 1/2·NCT00262470·150 enrolled

CAR1 trial

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

Terminated·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1/2·NCT00547911·14 enrolled

7 more indications

Methamphetamine Abuse1 trial

Pilot Study of Entacapone for Methamphetamine Abuse

Completed·OOregon Health and Science University·Phase 1·NCT02058966·29 enrolled

Efficacy1 trial

COMT Polymorphism and Entacapone Efficacy

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00373087·60 enrolled

Idiopathic Parkinson's Disease1 trial

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Completed·BBial - Portela C S.A.·Phase 3·NCT01568073·600 enrolled

Infusion1 trial

Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors

Completed·UUppsala University·Phase 4·NCT00906828·10 enrolled

Weight loss1 trial

Effect of Entacapone on Bodyweight Loss in Obese Population

Unknown status·KKaichun Wu·Phase 1/2·NCT02349243·30 enrolled

Treatment1 trial

Entacapone Combination With Imatinib for Treatment of GIST

Completed·XXiangya Hospital of Central South University·Phase 1·NCT04006769·5 enrolled

Schizophrenia1 trial

Entacapone Augmentation for Schizophrenia

Completed·RRambam Health Care Campus·N/A·NCT00192855·52 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 19, 1999

COMTAN

NDA NDA020796

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for entacapone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — entacapone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for entacapone. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020796). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Orion Corporation, Orion Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Orion Corporation, Orion Pharma

Comtan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Parkinson's Disease3 trials

Levodopa2 trials

Tics2 trials

Orthostatic Intolerance1 trial

CAR1 trial

Methamphetamine Abuse1 trial

Efficacy1 trial

Idiopathic Parkinson's Disease1 trial

Infusion1 trial

Weight loss1 trial

Treatment1 trial

Schizophrenia1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News